863604-71-1

Basic information

• Product Name: BenzenaMine, 5-broMo-N-(1-Methylethyl)-2-nitro-
• Synonyms: BenzenaMine, 5-broMo-N-(1-Methylethyl)-2-nitro-;5-Bromo-N-isopropyl-2-nitroaniline
• CAS NO: 863604-71-1
• Molecular Formula: C₉H₁₁BrN₂O₂
• Molecular Weight: 259.09984
• Mol File: 863604-71-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 343.2±32.0 °C(Predicted)
• Appearance: /
• Density: 1.521±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.80±0.25(Predicted)
• CAS DataBase Reference: BenzenaMine, 5-broMo-N-(1-Methylethyl)-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 5-broMo-N-(1-Methylethyl)-2-nitro-(863604-71-1)
• EPA Substance Registry System: BenzenaMine, 5-broMo-N-(1-Methylethyl)-2-nitro-(863604-71-1)

Safety Data

• Hazardous Substances Data: 863604-71-1(Hazardous Substances Data)

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 75-31-0 isopropylamine 
• 51686-78-3 2,4-dibromonitrobenzene 

Downstream Products

• 1038408-35-3 4-bromo-N²-(propan-2-yl)benzene-1,2-diamine 

Relevant articles and documents

1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS

The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3,R4, R5, R6, N-Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.